The biopharmaceutical sector has entered a pivotal period of clinical and corporate transitions, marked by breakthrough data in rare metabolic disorders and strategic realignments in the endocrine and cardiovascular therapeutic spaces. On November 13, 2026, Rezolute, a late-stage biotechnology firm specializing in ultra-rare metabolic diseases, announced positive preliminary results from its ongoing Phase 3 upLIFT study. The study evaluates ersodetug, a potential first-in-class treatment for tumor-induced hyperinsulinism (HI), a condition characterized by refractory hypoglycemia that poses severe risks to patient survival and quality of life. The clinical success reported by Rezolute coincides with a major structural reorganization at Spruce Biosciences, which is spinning off its endocrinology assets into a new entity, Adrenyx Biosciences, and new health economic data from Amgen reinforcing the value of early intervention in cardiovascular disease.
Rezolute and the upLIFT Study: Addressing Refractory Hypoglycemia
The Phase 3 upLIFT study is a registrational, single-arm, open-label trial designed to evaluate the efficacy and safety of ersodetug in patients suffering from tumor hyperinsulinism. This rare condition arises from two primary sources: insulin-secreting islet cell tumors, known as insulinomas, and non-islet cell tumors (NICTs), such as sarcomas or hepatocellular carcinomas. Both types lead to an over-activation of the insulin receptor—either through the overproduction of insulin or the secretion of insulin-like substances such as IGF-2—resulting in dangerously low blood sugar levels that are often resistant to standard therapies.
The primary efficacy endpoint of the upLIFT study was defined as the proportion of patients achieving at least a 50% reduction from baseline in their glucose infusion rate (GIR). GIR is a critical clinical metric representing a patient’s dependency on intravenous glucose to maintain stable blood sugar levels. According to the data evaluation conducted on November 5, 2026, the study met this primary endpoint. To reach statistical significance, the lower bound of the 95% confidence interval for the responder rate had to exceed 30%. With 13 of the 16 enrolled participants already meeting the responder criteria, the study has comfortably surpassed the requirement of nine responders (56%).
Of the 13 responders identified to date, 12 achieved the secondary but highly significant milestone of complete discontinuation of intravenous glucose. This clinical outcome suggests that ersodetug may offer a path toward hospital discharge and a return to oral-based management for patients previously tethered to constant IV support. Safety data remain encouraging, with the drug being well-tolerated and no drug-related adverse events reported during the pivotal or extension phases.
The Pathology and Unmet Need in Tumor Hyperinsulinism
Tumor HI represents a significant challenge in oncology and endocrinology due to its high morbidity. For patients with malignant insulinomas, the overproduction of insulin is continuous and autonomous, leading to neuroglycopenic symptoms, seizures, and potential brain damage. In cases of NICTs, the tumors secrete large quantities of "big" IGF-2, which mimics insulin’s effect on receptors throughout the body.
Ersodetug’s mechanism of action is distinct from existing treatments. As a fully human monoclonal antibody, it binds allosterically to the insulin receptor, effectively dampening its over-activation. Because it acts downstream of the tumor’s hormone secretion, it remains effective regardless of whether the hypoglycemia is driven by insulin or IGF-2. This "universal" potential is what distinguishes ersodetug from traditional therapies like diazoxide or somatostatin analogues, which often fail in severe tumor-related cases.
Rezolute’s leadership has indicated that these Phase 3 results mirror the outcomes seen in the company’s expanded access programs over the last several years. With the pivotal period of the study nearing completion, the company expects to present full statistical analyses by mid-December 2026. This timeline sets the stage for a formal discussion with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027, with the goal of advancing both congenital and tumor HI programs toward regulatory approval.
Spruce Biosciences and the Formation of Adrenyx Biosciences
In a significant corporate move on November 9, 2026, Spruce Biosciences announced the separation of its CRHX-101 program into a newly formed, wholly-owned subsidiary named Adrenyx Biosciences. This strategic "Separation" is intended to create two independent, publicly traded companies with distinct therapeutic focuses. Spruce Biosciences will remain dedicated to neurological disorders, specifically focusing on its TA-ERT program for Mucopolysaccharidosis Type IIIB (MPS IIIB), while Adrenyx will operate as a pure-play endocrinology firm.
The logic behind the spin-off rests on the need for dedicated capital and specialized management for the CRHX-101 program. CRHX-101 (formerly SPR-202) is a monoclonal antibody designed to treat classic Congenital Adrenal Hyperplasia (CAH) by selectively neutralizing corticotropin-releasing hormone (CRH). By targeting the very top of the hormone signaling cascade, CRHX-101 aims to control adrenal androgen excess without the heavy reliance on high-dose glucocorticoids, which currently cause significant side effects such as growth impairment and metabolic complications in CAH patients.
Samir Gharib, who will lead Adrenyx as President and CEO while maintaining his role as CFO of Spruce, emphasized that the new structure allows the CRHX-101 program to be advanced by a team with a specific legacy in CAH development. The separation is expected to be finalized in the first half of 2027 through a pro rata distribution of Adrenyx common stock to Spruce stockholders.
Financial and Clinical Milestones for the New Entity
The transition is supported by a robust financial framework. On November 6, 2026, Adrenyx entered into a secured convertible note purchase agreement with a leading institutional biotechnology investor for up to $10 million, with an initial $5 million already issued. Furthermore, a private placement of up to $50 million is expected to coincide with the distribution of shares. These funds are strictly earmarked for the development of CRHX-101 and cannot be used for Spruce’s neurological operations.
Adrenyx’s immediate priorities include completing Investigational New Drug (IND)-enabling activities and filing with the FDA to initiate clinical trials. Meanwhile, Spruce Biosciences is preparing for its own major milestone: a planned Biologic License Application (BLA) submission for TA-ERT in December 2026, targeting a potential commercial launch for MPS IIIB in 2027.
Amgen at AHA 2026: The Economic Argument for Early LDL-C Lowering
Parallel to these developments in rare disease, Amgen presented new data at the American Heart Association (AHA) Scientific Sessions 2026 that could reshape the standard of care for cardiovascular risk management. The findings focus on Repatha (evolocumab), a PCSK9 inhibitor, and its role in both primary and secondary prevention of cardiovascular events.
The highlight of the presentation was the first independent health economic analysis of the Phase 3 VESALIUS-CV trial. Conducted by the Duke Clinical Research Institute in collaboration with Harvard’s TIMI Study Group, the analysis evaluated high-risk patients who had not yet suffered a heart attack or stroke. The data revealed that Repatha is highly cost-effective, performing approximately 36% below the standard cost-effectiveness benchmarks established by the American College of Cardiology (ACC) and the AHA.
This economic validation is critical because it addresses long-standing barriers to the adoption of intensive lipid-lowering therapies. While the clinical benefits of PCSK9 inhibitors have been well-documented, their cost has often limited their use to secondary prevention (patients who have already had an event). Amgen’s new data suggests that treating "primary prevention" patients—those at high risk due to diabetes or established atherosclerosis but without a prior event—is not only clinically sound but also economically justifiable.
Long-Term Safety and Primary Prevention Insights
The VESALIUS-CV trial, which included over 12,000 patients, demonstrated a 25% relative reduction in the risk of coronary heart disease death, heart attack, or ischemic stroke. Furthermore, it showed a 36% reduction in the risk of heart attack specifically. In a lipid sub-study, patients adding Repatha to statin therapy achieved median LDL-C levels of 45 mg/dL, compared to 109 mg/dL in the placebo group.
Amgen also provided updates from the FOURIER-OLE (Open Label Extension) study, which is the longest trial of a PCSK9 inhibitor to date. With some patients followed for up to 8.4 years, the study confirmed that the reduction in LDL-C is sustained and that no new long-term safety concerns have emerged. More than 85% of patients in the extension study achieved LDL-C levels below 40 mg/dL.
These findings support a shift toward more aggressive, earlier intervention. As cardiovascular disease remains a leading cause of death globally, with a significant portion of events occurring in individuals without a prior history, the ability to prove the cost-effectiveness of early treatment is a major step toward changing clinical guidelines and payer policies.
Broader Implications for the Pharmaceutical Industry
The events of early November 2026 underscore several broader trends in the pharmaceutical industry: the move toward precision medicine in rare diseases, the strategic streamlining of corporate structures to maximize asset value, and the increasing importance of health economics in drug adoption.
Rezolute’s success in tumor HI highlights the potential for monoclonal antibodies to solve complex metabolic problems by targeting receptors rather than just supplementing or suppressing hormones. If approved, ersodetug could set a new precedent for the treatment of refractory hypoglycemia across multiple indications, including post-bariatric surgery complications.
The Spruce-Adrenyx separation reflects a growing trend where mid-cap biotech firms split their pipelines to prevent "conglomerate discounts" and allow investors to choose between different risk profiles—in this case, the high-unmet-need neuro-pediatric space versus the specialized endocrine market.
Finally, Amgen’s data at AHA 2026 reinforces the "lower is better" and "earlier is better" philosophy in lipidology. By providing the economic evidence to back up clinical outcomes, Amgen is positioning Repatha as a foundational therapy for a much broader patient population, potentially preventing thousands of first-time cardiovascular events.
As the industry moves into 2027, the focus will shift to regulatory filings and the practical integration of these therapies into clinical practice. For patients with tumor hyperinsulinism, CAH, or high cardiovascular risk, these developments represent a significant advancement in the quest for more effective and sustainable treatment options.
